Aurisco Pharmaceutical Co Ltd (605116) — Cash Flow-to-Debt Ratio
Aurisco Pharmaceutical Co Ltd (605116) has a Cash Flow-to-Debt Ratio of 0.22x as of December 2024, meaning its operating cash flow of CN¥332.41 Million could theoretically repay 0% of its total liabilities (CN¥1.55 Billion) in one year. See Aurisco Pharmaceutical Co Ltd (605116) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aurisco Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Aurisco Pharmaceutical Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Aurisco Pharmaceutical Co Ltd.
Annual Cash Flow-to-Debt Ratio for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year debt coverage analysis for Aurisco Pharmaceutical Co Ltd. Check Aurisco Pharmaceutical Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.22x | CN¥332.41 Million | CN¥1.55 Billion | ▼ -66.2% |
| 2023 | 0.64x | CN¥385.61 Million | CN¥607.03 Million | ▲ +33.1% |
| 2022 | 0.48x | CN¥166.41 Million | CN¥348.68 Million | ▼ -49.5% |
| 2021 | 0.94x | CN¥201.57 Million | CN¥213.44 Million | ▼ -34.8% |
| 2020 | 1.45x | CN¥214.48 Million | CN¥147.98 Million | ▼ -0.9% |
| 2019 | 1.46x | CN¥179.90 Million | CN¥122.96 Million | ▲ +77.5% |
| 2018 | 0.82x | CN¥109.77 Million | CN¥133.16 Million | ▼ -7.4% |
| 2017 | 0.89x | CN¥117.91 Million | CN¥132.44 Million | — |